We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+12.67%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.74B
AUM Growth
+$261M
Cap. Flow
+$250M
Cap. Flow %
14.34%
Top 10 Hldgs %
44.01%
Holding
80
New
16
Increased
10
Reduced
40
Closed
8

Top Buys

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$111M
2
BBIO icon
BridgeBio Pharma
BBIO
+$75.8M
3
STOK icon
Stoke Therapeutics
STOK
+$50.2M
4
QURE icon
uniQure
QURE
+$38.2M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$25.4M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$34.5M
2
ZGNX
Zogenix, Inc.
ZGNX
+$24.8M
3
ASND icon
Ascendis Pharma A/S
ASND
+$23.9M
4
ARGX icon
argenx
ARGX
+$15.9M
5
ANAB icon
AnaptysBio
ANAB
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
26
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$22.6M 1.3%
175,000
-125,000
-42% -$14.8M
CCXI
27
DELISTED
ChemoCentryx, Inc.
CCXI
$22M 1.26%
2,365,280
-160,620
-6% -$1.86M
ARGX icon
28
argenx
ARGX
$53.4B
$21.2M 1.22%
150,000
-125,000
-45% -$15.9M
ARRY
29
DELISTED
Array Biopharma Inc
ARRY
$20.8M 1.2%
450,000
-50,000
-10% -$1.4M
MRTX
30
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$20.6M 1.18%
+200,000
New +$15.6M
TWST icon
31
Twist Bioscience
TWST
$5.72B
$20.5M 1.18%
706,064
– –
SAGE
32
DELISTED
Sage Therapeutics
SAGE
$18.3M 1.05%
100,000
-30,000
-23% -$5.12M
EIDX
33
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$17.2M 0.99%
551,921
+44,357
+9% +$1.2M
CNST
34
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$15.6M 0.9%
1,271,685
-2
-0% -$22
VRTX icon
35
Vertex Pharmaceuticals
VRTX
$121B
$15.6M 0.9%
+85,000
New +$14.9M
NXTC icon
36
NextCure
NXTC
$16.7M
$15M 0.86%
+83,333
New +$17.3M
AKRO
37
DELISTED
Akero Therapeutics
AKRO
$14.7M 0.84%
+767,842
New +$14.6M
GOSS icon
38
Gossamer Bio
GOSS
$82.2M
$14.3M 0.82%
643,129
-10,000
-2% -$191K
NKTR icon
39
Nektar Therapeutics
NKTR
$2.39B
$14.2M 0.82%
26,667
-6,666
-20% -$3.34M
XFOR icon
40
X4 Pharmaceuticals
XFOR
$374M
$13.4M 0.77%
29,680
+21,255
+252% +$10.8M
EIGR
41
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$12.2M 0.7%
+38,333
New +$13.3M
INSP icon
42
Inspire Medical Systems
INSP
$1.44B
$12.1M 0.7%
200,000
-50,000
-20% -$2.69M
PHAS
43
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$11.9M 0.68%
906,229
+66,587
+8% +$816K
ARNA
44
DELISTED
Arena Pharmaceuticals Inc
ARNA
$11.7M 0.67%
200,000
-50,000
-20% -$2.58M
HSACU
45
DELISTED
Health Sciences Acquisitions Corporation Units
HSACU
$11.4M 0.66%
+1,080,000
New +$11.2M
AUTL
46
Autolus Therapeutics
AUTL
$399M
$11.3M 0.65%
700,000
-150,000
-18% -$3.35M
RARX
47
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$10.5M 0.6%
350,000
-50,000
-13% -$1.15M
ZLAB icon
48
Zai Lab
ZLAB
$2.06B
$10.5M 0.6%
300,000
-50,000
-14% -$1.47M
ORTX
49
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$10.2M 0.59%
73,033
+8,019
+12% +$1.41M
AMRN
50
Amarin Corp
AMRN
$300M
$9.7M 0.56%
25,000
-5,000
-17% -$1.83M
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2019 Portfolio in Review

As of Q2 2019, Cormorant Asset Management held 80 positions worth $1.74B, up 18% from $1.48B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management deployed $250M of net new capital in Q2 2019, opening 16 new positions and adding to 10 existing holdings. Its largest new stake was Turning Point Therapeutics, Inc. Common Stock: 3,122,367 shares worth $127M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was InflaRx, an estimated $34.5M trimmed.

  • Cormorant Asset Management's largest Q2 2019 buy was Turning Point Therapeutics, Inc. Common Stock: 3,122,367 shares worth $127M.
  • Cormorant Asset Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019, an estimated $25.4M increase.
  • Cormorant Asset Management's biggest Q2 2019 reduction was InflaRx, cutting an estimated $34.5M.
  • Cormorant Asset Management fully exited Zogenix, Inc. in Q2 2019, selling an estimated $24.8M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $1.74B portfolio in Q2 2019.
  • Cormorant Asset Management opened 16 new positions and closed 8 in Q2 2019.
  • Cormorant Asset Management's portfolio value rose 18% quarter-over-quarter to $1.74B.

Based on Cormorant Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.